

# **BIONEEDS**



### **Table Of Contents**

- Corporate Overview
- Drug Development Services Overview
- Early to Late Phase Clinical Trials
- Bioanalytical Research Capabilities
- Large Molecule Bioanalysis
- Biopharmaceutics & Data Science
- Recognitions
- Why Veeda?





# Corporate Overview

### **Veeda Group**



- Veeda Clinical Research Limited ("Veeda") together with its subsidiary, Bioneeds India Private Limited ("Bioneeds"), and its joint venture, Ingenuity Biosciences Private Limited ("Ingenuity"), (together referred to as the "Veeda Group") offers a comprehensive portfolio of clinical, preclinical and bio/analytical services to support innovator, biosimilar and generic drug development programs of our global clientele
- We are an independent, institutional investors owned, Board governed and professionally managed contract research group offering scientific leadership, global quality management systems and long term operational and financial stability through a continuing investment in our people, processes, systems, infrastructure and technology and a deep commitment to quality
- Together, we serve clients globally in the following industries:
  - Pharmaceutical and Biopharmaceutical
  - Agrochemical and Industrial Chemicals
  - Herbal/Nutraceuticals
  - Medical Devices

### **Our Global Foot Print**





### **Corporate Philosophy**

### veeda lingi exert. BIONEEDS





#### **Vision**


In an industry where innovation is increasingly multifaceted and collaborative, we aspire to be the research partner of choice for innovative (bio)pharmaceutical companies worldwide for their critical product development programs

#### **Mission**

To be the pre eminent independent Indian contract research Organization, with global execution capabilities, distinguished by the breadth of our services and by excellence in the quality of our Scientific and regulatory knowledge Research design, execution and insights and Client centricity

### **Quality Framework**

"Our management is committed to continuous improvement in the effectiveness of our Quality culture, to providing quality research solutions that meet sponsor and regulatory requirements and to protecting the rights, safety and well being of the study volunteers"



Focus on implementing policies & nurturing individual behavior to sustain our culture of quality



**Balanced Score Cards (BSC)** for augmenting corporate strategy

3 BIONEEDS

Ingenuity

veeda doctoreast



**Quantifiable Performance** Metrics for all departments

Individual KPI's & KRA's linked to BSC



**Continuous process** improvement

### **Regulatory Credentials**

veedadroi exam. BIONEEDS Ingenuity

- 82 successful regulatory audits till date
- 09 successful regulatory audits in last 24 months



### **Our Values**








# Drug Development Services Overview



### Your Drug Development Journey



Ingenuity

**BIONEEDS** 

veeda doctossort.

### **Drug Development Service**

veedadnoshesent,



**BIONEEDS** 

Assay development Pharmacodynamics

- Pharmacokinetics
- Immunogenicity
- Biomarker Assessment

Immunogenicity Testing

**Characterization** 

**Other Services** 

- Screening ELISA
- Confirmatory ELISA
- NAb Assay
- In vitro Immunogenicity
- Intact mass , Reduced Mass
- Subunit analysis
- Peptide mapping
- Disulfide bond locations
- Glycan analysis
- Critical reagent preparation
- HCP and HCD
- Polyclonal and Monoclonal antibody production
- Cascade Immunization







#### Partners in creating a healthier tomorrow

Discovery and Development







### Infrastructure

#### VEDANT •

Clinical. **Bio-analytical facility** 

#### **SHIVALIK** •

**Dedicated Clinical** facility

#### SKYLAR

Common screening facility for both Shivalik and Vedant

#### ARCHIVES

Internal archival area in each facility. Separate long term archival facility at Changodar and Uniha

#### MAGNET CORPORATE PARK

Administrative office

#### **MEHSANA**

Clinical and Screening facility

#### INSIGNIA

.

Dedicated **Bio-analytical facility** 



(

### Spread across 14 clinics

170 Beds +

7 Special care beds +

Shivalik


12 Intensively monitored beds to conduct Phase I studv



### **Phase I Trial Experience**

veedadroneexet, BIONEEDS







# Patient based PK end point studies experience



Therapeutic Areas and Indications	No. of Studies	No. of Patients	Type of Study		
Antiviral					
HIV	1	48	PK Endpoint Study		
Oncology					
Chronic Myeloid Leukemia (CML)	6	160	PK Endpoint Study		
CML & Gastrointestinal stomal tumor (GIST)	1	40	PK Endpoint Study		
Metastatic Breast Cancer (MBC)	3	203	PK Endpoint Study		
Metastatic Breast Cancer (MBC) and Colo Rectal Cancer (CRC)	2	99	PK Endpoint Study		
Multiple Myeloma (MM)	1	54	PK Endpoint Study		
Orthopaedic Cancer	1	58	PK Endpoint Study		
Ovarian Cancer	2	120	PK Endpoint Study		
Ovarian and MBC	3	202	PK Endpoint Study		
Renal Cell Carcinoma (RCC)	3	86	PK Endpoint Study		
Psychiatry					
Schizophrenia	7	463	PK Endpoint Study		
Rheumatology					
Rheumatoid Arthritis (RA) and Psoriasis	1	42	PK Endpoint Study		

### **Clinical End Point Studies Experience**



Therapeutic Area	Completed Studies	Study Phase
Oncology	6	Phase 1, Phase2
Orthopaedic	3	Phase 3
Ophthalmology	1	Bioequivalence Clinical Endpoint

### **Our Ongoing Patient Trials for Diverse Therapy Area**



Study Type	Therapeutic Area	Indication	
Phase I/II	Thrombolytic	Acute ST segment	
FildSe I/II	Thrombolytic	Elevation Myocardial Infarction	
Pk end point	Oncology	Breast Cancer	
Pk end point	Oncology	Advance prostatic cancer	
Phase II	COVID-19	mildly symptomatic patients with SARS-CoV-2 Infection (Covid-19)	
Pk End Point	Oncology	Ovarian Cancer	
Clinical End Point	Ophthalmic	open-angle glaucoma or ocular hypertension	
Phase I	Oncology	Solid Tumor	
Pk End Point	Hematology	Iron Deficiency Anemia	
Pk End Point	Oncology	Breast Cancer	
Phase II/III	COVID-19	SARS-CoV-2 Infection in healthy subject	

### Veeda's Vaccine Study Experience




### Vaccine Study (Covid)

- A randomized, double-blinded, placebo-controlled, parallel-group, multi-centre, adaptive, seamless bridging study followed by a phase II/III study to assess the safety and immunogenicity of Anti-COVID-19 AKS-452 vaccine for SARS-Cov-2 infection in Indian healthy subjects.
- Phase: Bridging phase II/III study
- No of Subject: 100 (Bridging) 1500 (Phase II/III study)
- Sites: 12 centers

#### Vaccine Study (Polio)

- Open Label Phase 1 Clinical Study for Evaluation of Safety and Immunogenicity of Sabin based Inactivated Polio Vaccine in Healthy Adult Human Male Subjects
- No. of subjects- 3

### **Combined Team Experience in Clinical Trials**



**BIONEEDS** 

Ingenuity

veeda decaterovers

### Integrated Service Model Drug Development

- Centre for Biosimilar Excellence Laboratory: Synergy between Somru and Veeda
- Somru BioScience brings in scientific and regulatory expertise in the area of bioanalysis, which includes

BIONEEDS

veedadoost

- · Custom reagent development and qualification,
- Method development and validation
- Pre-clinical/clinical sample analysis
- Technology transfer from Somru [ADA, PK, Nab validated assays]
- Somru supplies all Critical Reagents
- Ingenuity team performs Method Validation and Sample Analysis in consultation with Somru team

### **Biosimilar Solutions**

veedadinatesent, BIONEEDS Ingenuity

- Biocomparability Testing Solutions Wide range of Biocomparability testing solutions so that you can
  test your biosimilar early in the development process and minimize the risk of failure during late phases of the
  drug development.
- Bioassay Solutions Evaluate functionality of your biosimilar using cell-based assay based on the drug's mechanism of actions such as cell proliferation, cell viability, cell signaling, receptor activation, and ligand binding assays to measure various downstream proteins.
- Antibody Functionality Testing Evaluate antibody function utilizing following assays: ADCC assays, CDC assays, Fc Receptor binding assays (i.e, FcyRI(CD64), FcyRII(CD32a), FcyRIII(CD16a), and FcRn etc.) and C1q binding assays.

### Somru Expertise — Breadth and Depth

#### **Innovative Technologies:**

- mAbY<sup>™</sup> Recombinant antibody platform
- Aegyris<sup>™</sup> Laboratory Informatics Solutions
- Intelli.b<sup>™</sup> Biosimilar Characterization Solutions

In-depth Experience: approximately 122 validated methods supporting 70 biosimilar/biobetter molecules

**Regulatory experience:** Global regulatory - US FDA, EMA and Strategy meetings





### **PK Assay Summary: Biosimilars**



Product Name	Cetuximab	Rituximab	Bevacizumab	Trastuzumab	Denosumab	Adalimumab	Ranibizumab
Detection Method	Colorimetric	Colorimetric	Colorimetric	Colorimetric	Colorimetric	Colorimetric	Colorimetric
Provision (0(C))	Intra assay: 4% to 9%	Intra assay: 2% to 6%	Intra assay: 2% to 6%	Intra assay: 8% to 11%	Intra assay: ≤ 10%	Intra assay: 5% to 10%	Intra assay: ≤ 10%
Precision (%CV)	Inter assay: ≤ 10%	Inter assay: ≤ 5%	Inter assay: ≤ 5%	Inter assay: ≤ 9%	Inter assay: ≤ 15%	Inter assay: ≤ 11%	Inter assay: ≤ 15%
Accuracy (%RE)	less than 7%	less than 6%	less than 4%	less than 7%	less than 15%	less than 8%	less than 15%
Sensitivity	156 ng/mL	55 ng/mL	40 ng/mL	63 ng/mL	25 ng/mL	156 ng/mL	250 pg/mL
Dilutional Linearity	up to 40 fold	up to 1000 fold	up to 40 fold	up to 1000 fold	Data not available	up to 40 fold	Data not available
Hook effect	No (up to 400 µg/mL)	No (up to 500 µg/mL)	No (up to 200 µg/mL)	No (up to 300 µg/mL)	Data not available	No (up to 500 µg/mL)	Data not available

### **PK/ADA Validated Methods List**



Molecule	Validated Method		Reference Product
	РК	ADA	
Adalimumab	$\checkmark$	$\checkmark$	Humira
Trastuzumab	$\checkmark$	$\checkmark$	Herceptin
Bevacizumab	$\checkmark$	$\checkmark$	Avastin
Ranibizumab	$\checkmark$	$\checkmark$	Lucentis
Pegfilgrastim	$\checkmark$	$\checkmark$	Neulasta
Infliximab	$\checkmark$	$\checkmark$	Remicade
Rituxumab	$\checkmark$	$\checkmark$	Rituxan
Insulin Glargine	$\checkmark$	$\checkmark$	Lantus
Insulin Aspart	$\checkmark$	$\checkmark$	Novolog
Aflibercept	$\checkmark$	$\checkmark$	Eylea
Etanercept	$\checkmark$	$\checkmark$	Enbrel
Erythropoietin	$\checkmark$	$\checkmark$	Epogen
Pembrolizumab	$\checkmark$	$\checkmark$	Keytruda
Nivolumab	$\checkmark$	$\checkmark$	Opdivo
Omalizumab	$\checkmark$	$\checkmark$	Xolair
Denosumab	$\checkmark$	$\checkmark$	Prolia

### **Veeda's Biosimilar Experience**

Ongoing Studies	Therapy Area	No. Of Patients
Omalizumab		
Filgrastim & Pefilgrastin		
Recombinant FSH		

#### **Our Team's Cumulative Large Molecule Experience**

Molecule Name			
Filgrastim	Filgrastim		
Erythropoetin	Pegfilgrastim		
Denosumab	Tocilizumab		
FSH	Teriparatide		
Romiplostim	H1N1 Vaccine		
Ranibizumab	Covid Vaccine		

Partners in creating a healthier tomorrow

**BIONEEDS** 

Ingenuity

veedadocatement

### **Veeda's Biosimilar Experience- Ongoing Studies**



#### Omalizumab

A randomized, double blind, two-arm, parallel group, single dose comparative pk, pd and immunogenicity study comparing adl-018 lyophilized powder with us-licensed xolair lyophilized powder administered through subcutaneous route in healthy adult subjects

• 120 subjects (60 in each treatment arm) (+ stand by subjects)

A randomized, double blind, three-arm, parallel group, single dose comparative pk, pd, safety and immunogenicity study comparing adl-018 with us-licensed xolair and eu-approved xolair administered through subcutaneous route in healthy adult subjects

306 subjects (102 in each treatment arm) (+ stand by subjects)

#### Pegfilgrastim

A Two-Part, Randomized, Double-Blind, Single-Dose, Three-Period, Crossover Study Evaluating the Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, and Immunogenicity between BSC-0826 and US-licensed Neulasta and EU-approved Neulasta Part 1, and Randomized, Double-Blind, Two-Dose, Parallel Arm Study Evaluating the Safety and Immunogenicity in Part 2 of BSC-0826 to EU-Neulasta following Subcutaneous Administration to Healthy Subjects

- Part 1: A total of one hundred and eighty-six (186) healthy adult male and female subjects will be enrolled. Study will be conducted in multiple groups.
- Part 2: Two hundred and forty (240) healthy, adult male and female subjects will be enrolled (120 subjects per treatment arm).

### **Veeda's Biosimilar Experience- Ongoing Studies**



#### Filgrastim

A Two-Part, Randomized, Open-Label, Single-Dose, Multiple-Dose, Parallel Arm Study Evaluating the Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of Biosimilar Sciences Filgrastim (BSC-1020) to Neupogen Following Subcutaneous Administration to Healthy Subjects

- **Part 1:** A total of two hundred and one (201) healthy adult male and female subjects will be enrolled. Subjects will be randomized to 1 of 3 treatment groups (67 subjects per treatment).
- **Part 2:** A total of one hundred thirty four (134) healthy adult male and female subjects will be enrolled. Subjects will continue the study from Part 1 to Part 2 for Treatments A and B (67 subjects per treatment).

#### **Recombinant Follicle Stimulating Hormone**

A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study of Foligraf 900 IU (66.0 μg) / 1.5mL Solution for Injection in Prefilled Pen [Follicle Stimulating Hormone (Human Recombinant)] of Bharat Serums and Vaccines Limited, India and GONAL-f 900 IU (66.0 μg) / 1.5 mL solution for injection in pre-filled pen of Merck Serono at a dose of 300 IU in Healthy, Adult, Female, Human Subjects.

 In regards to ensure 36 completer subjects for the study, up to 72 healthy, adult, female, human subjects will be enrolled in the study.





Our ongoing vaccine studies:

#### **IgG Titer Studies:**

- IgG Titre Clinical studies involve the measurement of human anti-SP/RBD IgG titers in human serum samples
- RBD Specific target
- Method optimization and Validation, followed by clinical studies

#### **ELISPOT Studies:**

- The enzyme-linked immunospot [ELISPOT] **assay** is a highly sensitive immunoassay that measures the frequency of cytokine-secreting cells at the single-cell
- Expertise in PBMC isolation and culturing
- State-of-the-art infrastructure for ELISPOT assays

#### **PRNT Studies: [Outsourced lab]**

- Measures the levels of Neutralizing antibodies in an individual against SARS-CoV-2
- BSL3- Facility and scientific liaison between the client and the lab performing PRNT assay



### **Overview of Biosimilar** Lab - Infrastructure

 Ingenuity Biosciences has state-of-the-art Biosimilar laboratory Bioequivalence study center co-located with Insignia site of Veeda clinical research

Equipment & Software	No.
Microplate Reader	1
Microplate Washer	2
BOD Incubator	1
Deep Freezer (-20°C ± 5°C)	1
Refrigerator	1
Aegyris Software	1



BIONEEDS

Indenuity

veedadocatereaut

### **Biosimilar Lab Infrastructure**





#### **Microplate Reader**

Synergy<sup>™</sup> H1 is a flexible monochromator-based multi-mode microplate reader that can be turned into a high-performance hybrid system with the addition of a filter-based optical module. The monochromator optics use a third generation quadruple grating design that works at any excitation or emission wavelength with a 1 nm step.



#### **Microplate Washer**

The 50<sup>™</sup> TS Washer offers functionality that is unsurpassed in its class. The color touchscreen provides a visual interface that makes creating protocols fast and intuitive. Its performance for conventional plate washing is excellent, and it is also ideal for cell-based assay washing and for processing biomagnetic or polystyrene bead and vacuum filtration protocols.



#### **BOD** incubator

BOD Incubator (Bio-Oxygen Demand) are used to maintain temperature for test tissue culture growth, storage of bacterial cultures and incubation where high degree of constant temperature accuracy is required. Thermolab BOD Incubators provide with accurate conditions and uniformity throughout the chamber.

### **Critical Instruments and Monitoring**

- BD FACSLyric Flow cytometer
- Shimadzu Nexera UHPLC and HPLC
- Q Exactive Orbitrap Mass Spectrometer -LC-MS/MS
- ICP-MS
- 2D Electrophoresis- BioRad
- Plate Readers Softmax Pro and Biotek
- Real time PCR- Thermo Fisher
- Bioreactors (5 lts)
- Ekta Purification system
- Gas Chromatography
- Stability Chambers

# Qualified instruments, Software validated and 21 CFR Part 11 compliance















veedadocatement





# veeda invariesent, BBIONEEDS Ingenuity

### **LC MS Capabilities**

#### **Q Exactive Orbitrap Mass Spectrometer**

Make : Thermo Fisher Scientific Inc Model : Q Exactive Basic

#### **UHPLC – Front End**

Make : Shimadzu Corporation

Model: Shimadzu Nexera

#### Software components


Xcalibur 4.0.27.19 (Thermo Fisher Scientific Inc.) Biopharma Finder 2.0 Data Analysis Software



### **Flow Cytometry**







- Flow cytometry is a technique that can provide quantitative and qualitative information about biological cells and micro particles.
- The information is in the light that interacts with the cells as they pass one after another and one at a time through a narrow region illuminated by one or more lasers.
- Its design consists of fluidics, illumination optics, photo detection, data analysis, and, in some models cell sorting.

### **BD FACSLyric™ Flow Cytometry System**





#### Applications

- Study specific cell populations and sub-populations analysis
- Cell proliferations, Cell death and intracellular proteins analysis
- Cell surfaces markers Analysis (Example: CD54, CD86, CD3, CD4, CD8, CD14, CD 43, CD 34, CD19, CD20, CD56 etc.)
- Analysis of certain functional immune characteristics, biological effects associated with particular immune defects
- Bead-Based Multiplexed Assay for Simultaneous Quantification of intra cellular cytokines and secreted cytokines using specific fluorescence-labeled antibodies.

#### Specifications of the system:

- 3 lasers Blue, Red and Violet
- 12 fluorescence channels and 14 parameters.
- Acquisition rate: 35,000 events per second maximum
- Loading options: plates or tubes: Automated loader can accommodate 30 tubes and 96-well plate
- 21 CFR Part 11 compliant BD FACSuite<sup>™</sup> data management software (BD FACSuite-Version No.: 1.4)



# Bioanalytical Research



# **LCMS** Capabilities



Particulars of Capability	Drug Product
Intact/Subunit mass / reduced Mass	Proteins, Protein Conjugates, Peptides
Modifications at intact mass level	Monoclonal Antibodies, Proteins
Peptide Mapping and sequence coverage	Monoclonal Antibodies, Proteins
N Terminal and C Terminal sequence analysis	Monoclonal Antibodies, Proteins
Disulfide bonding analysis	Monoclonal Antibodies, Proteins
Glycan profiling of mAbs	Monoclonal Antibodies

# Infrastructure



### **Scale and Range**

- 46 LC-MS/MS machines
  - Insignia (33) and Vedant (13)
  - API 5500/4000/3200/3000/2000
  - Shimadzu 8060/8050/8040
  - Quattro Premier
- 2 ICP-OES
- Watson LIMS

### **Storage Capacity**



### **Plasma Sample:**

45 Deep freezers with capacity to store 11,25,000 samples at -80  $^{\circ}\mathrm{C}$ 



#### **IP Storage:**

- 3 Walking type stability chambers with overall capacity to store 34000 Ltr for retention at room temperature
- 4 Humidity chambers with overall capacity of 3200 Ltr
- 4 Pharmaceutical refrigerators having storage capacity of 3550 Ltr at 2-8 °C



# Large Molecules Bioanalysis

# Large Molecules Bioanalytical Experience



- Recently developed and validated below large molecules as per current EMEA guidance using commercially available kits by ELISA technique
  - Insulin Aspart and C peptide
  - Filgrastim
  - PTH (Teriparatide)
  - Denosumab
  - Romiplostim
- Enoxaparin: PD endpoint and Immunogenicity for FDA, EU and ANVISA submission
- Pipeline Project: Cetuximab

Sr. No.	Analyte	No. of samples analyzed	No. of samples analyzed for ISR	% of ISR samples within acceptance
1	G-CSF	2142	158	98.70%
2	Insulin Aspart	2139	158	94.90%
3	C- Peptide	2400	176	98.20%
4	PTH	340	34	88.33%

### Total studies : More than 40 studies ongoing (from Multisites globally, 20000 samples per year)

Our Broad Experience for NCE molecules with Global Pharmaceutical company

- Services provided: Sample management, method development, method validation and analysis of NCEs
- Sample receipt to analysis within 5 days
- Sponsor specific reports with e-CTD

•

- More than 64 methods developed and validated for NCEs
- Exploratory studies, e.g. skin tissues, plasma protein binding experiment, chiral impurity estimation in the sample

# **Central Bioanalytical Lab Experience**

# Handling Complex study - Multicenter study (which involved more than 35 sites (150 subjects, 10 Analytes)

- Required screening sample analysis within 10 days from sample collection
- Estimated 10 analytes for this study- Total 4 bio-analytical methods
- Provided sample collection kits to all sites- within stipulated time



## **Complex Methods Experience**

 Iron Sucrose: For Transferrin bound iron the serum samples are filtered through SPE cartridges to remove free and formulation bound iron while the filtrate contains TBI which is further analyzed by ICP OES.

3 BIONEEDS

veedadocatereaut

- Peptides (small molecules) by LCMSMS: sensitivity and extraction issues
  - Desmopressin
  - Leuprolide
  - Octreotide
- Biomarker analysis α1 Acid Glycoprotein AAG: Method HPLC-UV, large molecule (biomarker) validated method for clinical support.









# **Clinical Data Management Services**

**BIONEEDS** veeda docatamente

deliverables

**Medical Coding** 

Ingenuity

**Query Management** Real-time data viewing and reporting **CDASH** Compliant **CDM** Data Export/Transfer **Services** External Data handling Safety Data Management & Reconciliation

EDC and Paper Trial Set-Up & Management

> Data Management Plan (DMP)

CRF/eCRF design and development

**CRF** Annotation & Review

**Database Build** & Design

Data validation plan

Edit checks Programming & Testing

Data processing through double data entry

# **Biostatistics Capabilities**







Reconciliation and oversight



**Periodic tracking** 



Quick setup

### **Timely Database lock**

- Our team has experience in various statistical evaluations for •
  - Design of experiment (DoE) .
  - In-vitro population bioequivalence (PBE) .
  - In-vitro equilibrium binding •
  - Kinetic binding studies .
  - Dose proportionality studies •
  - Pharmacodynamics end point studies .
- Our team also has expertise in the prediction and simulation analysis

Key

**Strengths** 



# **Recognitions**

# **Recognitions**

veedadiricatesent, BIONEEDS

	Organization	Award Category	_			
	ASSOCHAM	Best Clinical Research Organization - India		organization	Award Category	
17 YEARS of excellence in	Welliess	Clinical Trial Company of the Year	E	BioSpectrum	Top CLRO Company Best Quality Clinical	
Clinical Research		Bharat Udhyog Ratan Award in Clinical Research	0	Proxis Media	Research Services in India	
2004		2018			2020	
2017			2019			
Organization	Award Category					
ProxisMedia	National Exc	cellence Award	Organization	n	Award Category	
A	Best Pharmaceutical CRO		17/0	Best	Best Quality Clinical Research	
Health & Safety Awar	ds Best Clinical	Research- India	The second secon		Organization in India	
	Best Clinical Re		PLANS		t Quality Clinical Researc	
	Mark of	Mark of Excellence			Organization in India	
PROST OF SULLIVAN	<ul> <li>Indian Clinical Research</li> <li>company</li> <li>of the year</li> </ul>		anne and an		Indian Clinical Research company of the year	
	OI tr	ie year			1 1 2	

## **Veeda Group Advantage**







# Thank you

For any further assistance kindly write to us at **info@veedacr.com** Visit us at **www.veedacr.com** 

